| Literature DB >> 26633986 |
Mohd-Al-Faisal Nordin1, Fathilah Abdul Razak1, Wan Harun Himratul-Aznita1.
Abstract
Bakuchiol is an active component of Psoralea glandulosa and Psoralea corylifolia, used in traditional Chinese medicine. The study aimed at investigating the antifungal activity of bakuchiol on planktonic and biofilm forms of orally associated Candida species. The antifungal susceptibility testing was determined by the broth micro dilution technique. Growth kinetics and cell surface hydrophobicity (CSH) of Candida were measured to assess the inhibitory effect of bakuchiol on Candida planktonic cells. Biofilm biomass and cellular metabolic activity were quantitatively estimated by the crystal violet (CV) and the 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assays. All Candida strains have been shown to be susceptible to bakuchiol with the MIC ranges from 12.5 to 100 μg/mL. Significant decrease in specific growth rates and viable counts demonstrates the inhibitory effect of bakuchiol on Candida planktonic cells. A brief exposure to bakuchiol also reduced CSH of Candida (P < 0.05), indicating altered surface properties of yeast cells towards hydrophobic interfaces. Biofilm biomass and cell metabolic activity were mostly decreased, except for C. glabrata (P = 0.29). The antifungal properties of bakuchiol on Candida species in this in vitro study may give insights into the application in therapeutic strategy against Candida infections.Entities:
Year: 2015 PMID: 26633986 PMCID: PMC4655055 DOI: 10.1155/2015/918624
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Chemical structure of bakuchiol.
Antifungal activity of bakuchiol against Candida species.
| Antifungal susceptibility testa ( | ||||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| Bakuchiol | ||||||
| MIC | 25 | 12.5 | >100 | 50 | 50 | 50 |
| MFC | 50 | 25 | >100 | 50 | 100 | 100 |
| Amphotericin B | ||||||
| MIC | 1.95 | 1.95 | 1.95 | 1.95 | 7.81 | 1.95 |
| MFC | 3.91 | 1.95 | 3.91 | 1.95 | 7.81 | 3.91 |
a(1) C. albicans ATCC 14053, (2) C. dubliniensis ATCC MYA-2975, (3) C. glabrata ATCC 90030, (4) C. krusei ATCC 14243, (5) C. lusitaniae ATCC 64125, and (6) C. tropicalis ATCC 13803.
Changes in the specific growth rates (µ) and the viable counts (CFU) of Candida species following bakuchiol exposure. The percentage denotes the inhibition of treated samples compared to the untreated ones.
| Microorganism | Treatmenta |
| Log10 CFU/mL (%) |
|---|---|---|---|
|
| Untreated | 1.73 ± 0.08 | 10.04 ± 0.03 |
| Bakuchiol | 0.70 ± 0.07 (59.5) | 7.24 ± 0.08 (27.9) | |
| Amphotericin B | 0.49 ± 0.10 (71.7) | 6.64 ± 0.05 (33.9) | |
|
| |||
|
| Untreated | 0.98 ± 0.14 | 8.32 ± 0.28 |
| Bakuchiol | 0.45 ± 0.24 (54.1) | 6.87 ± 0.42 (17.4) | |
| Amphotericin B | 0.74 ± 0.19 (24.5) | 7.36 ± 0.09 (11.5) | |
|
| |||
|
| Untreated | 1.80 ± 0.06 | 10.13 ± 0.08 |
| Bakuchiol | 1.11 ± 0.03 (38.3) | 8.34 ± 0.07 (17.7) | |
| Amphotericin B | 1.47 ± 0.13 (18.3) | 9.20 ± 0.07 (9.2) | |
|
| |||
|
| Untreated | 0.82 ± 0.20 | 8.63 ± 0.45 |
| Bakuchiol | 0.73 ± 0.15 (11) | 5.72 ± 0.35 (33.7) | |
| Amphotericin B | 0.55 ± 0.12 (32.9) | 6.32 ± 0.21 (26.8) | |
|
| |||
|
| Untreated | 1.09 ± 0.15 | 8.95 ± 0.36 |
| Bakuchiol | 0.42 ± 0.10 (61.5) | 6.90 ± 0.16 (22.9) | |
| Amphotericin B | 0.98 ± 0.24 (10.1) | 8.69 ± 0.50 (2.9) | |
|
| |||
|
| Untreated | 1.57 ± 0.14 | 9.80 ± 0.43 |
| Bakuchiol | 1.02 ± 0.18 (35) | 9.30 ± 0.23 (5.5) | |
| Amphotericin B | 0.91 ± 0.12 (42) | 8.63 ± 0.08 (11.9) | |
aTest concentration was prepared at 0.5 × MIC. P < 0.05 compared to the untreated samples.
Figure 2Cell surface hydrophobicity of Candida species following bakuchiol exposure. Data are represented as mean ± SD of three independent experiments performed in triplicate. Amphotericin B used as a positive control. Asterisk (∗) denotes the significant difference between treated samples and the untreated ones (one-way ANOVA; P < 0.05).
Figure 3Absorbance values of crystal violet solutions obtained from Candida biofilm formation following bakuchiol exposure. Data were represented as mean ± SD of three independent experiments performed in triplicate. Amphotericin B used as a positive control. Asterisk (∗) denotes the significant difference between treated samples and the untreated ones (one-way ANOVA, P < 0.05).
The metabolic activity of single and mixed biofilms when exposed to bakuchiol was measured. Values represent absorbance using XTT reduction assay.
| Biofilms | Untreated | Bakuchiol | Amphotericin B |
|---|---|---|---|
| Single species | |||
|
| 1.042 ± 0.049† | 0.417 ± 0.085 | 0.266 ± 0.046 |
|
| 0.279 ± 0.016 | 0.274 ± 0.029 | 0.174 ± 0.026 |
|
| 0.723 ± 0.040† | 0.896 ± 0.096 | 0.353 ± 0.061 |
|
| 0.467 ± 0.048 | 0.400 ± 0.085 | 0.228 ± 0.079 |
|
| 0.192 ± 0.016 | 0.182 ± 0.017 | 0.242 ± 0.030 |
|
| 0.351 ± 0.037 | 0.243 ± 0.032 | 0.376 ± 0.056 |
|
| |||
| Mixed species | |||
|
| |||
| + | 0.435 ± 0.024 | 0.205 ± 0.015 | 0.201 ± 0.023 |
|
| 1.023 ± 0.054† | 0.962 ± 0.104 | 0.527 ± 0.036 |
|
| 0.444 ± 0.014 | 0.315 ± 0.018 | 0.330 ± 0.032 |
|
| 0.292 ± 0.013 | 0.246 ± 0.014 | 0.232 ± 0.025 |
|
| 0.289 ± 0.019 | 0.210 ± 0.025 | 0.198 ± 0.015 |
† P < 0.01 compared to others in their respective groups; single and mixed species biofilms.
P < 0.05 compared to the untreated samples.
P < 0.05 compared to bakuchiol-treated samples.